Clindamycin Phosphate (Cleocin Phosphate)

Trade Name : Cleocin Phosphate

Pharmacia and Upjohn Company LLC

INJECTION, SOLUTION

Strength 150 mg/mL

CLINDAMYCIN PHOSPHATE Decreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Clindamycin Phosphate (Cleocin Phosphate) which is also known as Cleocin Phosphate and Manufactured by Pharmacia and Upjohn Company LLC. It is available in strength of 150 mg/mL per ml. Read more

Clindamycin Phosphate (Cleocin Phosphate) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Click to know price. Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

About GNH

No data

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Sterile Solution is for Intramuscular and Intravenous Use

Clostridium difficilen- C. difficile
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.

CLEOCIN PHOSPHATE Sterile Solution in vials contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid. Each mL contains the equivalent of 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative in each mL. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The chemical name of clindamycin phosphate is L--u03b1-D-Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2)-.
The molecular formula is CHCIN0PS and the molecular weight is 504.96.
The structural formula is represented below:
CLEOCIN PHOSPHATE IV Solution in the GALAXY plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid.
The plastic container is fabricated from a specially designed multilayer plastic, PL 2501. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.

No data

CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin).
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.
Indicated surgical procedures should be performed in conjunction with antibiotic therapy.
CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below:
Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, other streptococci (except ), and n
Skin and skin structure infections caused by , and anaerobes.
Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.
Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.
Septicemia caused by , streptococci (except ), and susceptible anaerobes.
Bone and joint infections including acute hematogenous osteomyelitis caused by and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

See .

No data

The following reactions have been reported with the use of clindamycin.

Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed.
Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.

If diarrhea occurs during therapy, this antibiotic should be discontinued (see box).
Clindamycin phosphate IM administration should be used undiluted
Clindamycin phosphate IV administration should be dilutedn- Array

No data

Each mL of CLEOCIN PHOSPHATE Sterile Solution contains clindamycin phosphate equivalent to 150 mg clindamycin, 0.5 mg disodium edetate; 9.45 mg benzyl alcohol added as preservative. When necessary, pH is adjusted with sodium hydroxide and/or hydrochloric acid. CLEOCIN PHOSPHATE is available in the following packages:
Store at controlled room temperature 20u00b0 to 25u00b0C (68u00b0 to 77u00b0F) [see USP].
CLEOCIN PHOSPHATE IV Solution in GALAXY plastic containers is a sterile solution of clindamycin phosphate with 5% dextrose. The single dose GALAXY plastic containers are available as follows:
Exposure of pharmaceutical products to heat should be minimized. It is recommended that GALAXY plastic containers be stored at room temperature (25u00b0C). Avoid temperatures above 30u00b0C.

No data

This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
Distributed by Pharmacia & Upjohn Co.Division of Pfizer Inc.New York, NY 10017
PREMIERProRx is a registered trademark of Premier Healthcare Alliance, L.P., used under license.
CLEOCIN PHOSPHATE IV Solution in GALAXY plastic containers is manufactured for Pfizer Inc by Baxter Healthcare Corporation, Deerfield, IL 60015.
Galaxy is a registered trademark of Baxter International Inc.
LAB-0696-14.0Revised: 2/2020

2 mL Vial NDC 0009-0302-02
CleocinPhosphaten clindamycin injection, USP
300 mg/2 mL*
(150 mg/mL) Rx only
For intramuscular or intravenous use
PREMIERProRxn

NDC 0009-0302-25Contains 25 of NDC 0009-0302-02
25u20142 mL Single Dose Vials
Cleocin Phosphaten clindamycin injection, USP
300 mg/2 mL* (150 mg/mL)
For intramuscular or intravenous use
PREMIERProRxn
Rx only

4 mL Vial NDC 0009-0602-04
Cleocin Phosphaten clindamycin injection, USP
600 mg/4 mL*
(150 mg/mL) Rx only
For intramuscular or intravenous use
PREMIERProRxn

NDC 0009-0602-25Contains 25 of NDC 0009-0602-04
25u20144 mL Single Dose Vials
Cleocin Phosphaten clindamycin injection, USP
600 mg/4 mL* (150 mg/mL)
For intramuscular or intravenous use
PREMIERProRxn
Rx only

6 mL Vial NDC 0009-0901-06
Cleocin Phosphaten clindamycin injection, USP
900 mg/6 mL*
(150 mg/mL) Rx only
For intramuscular or intravenous use
PREMIERProRxn

NDC 0009-0901-25Contains 25 of NDC 0009-0901-06
25u20146 mL Single Dose Vials
Cleocin Phosphaten clindamycin injection, USP
900 mg/6 mL* (150 mg/mL)
For intramuscular or intravenous use
PREMIERProRxn
Rx only

NDC 0009-3470-01
Cleocin Phosphate IV Solutionclindamycin injection
300 mg/ 50 mL* in 5% DEXTROSE Rx only
For Intravenous Use
Code 2G3470Sterile, Nonpyrogenic
GALAXY Single Dose Container
PREMIERProRxn
Distributed byPharmacia & Upjohn CoDivision of Pfizer IncNew York, NY 10017
PREMIERProRx is a registered trademarkof Premier Healthcare Alliance, L.P.,used under license.

2 x 12 x 50 mL Single Dose Containers Contains 2 boxes of 12 of NDC 0009-3470-01
Cleocin Phosphate IV Solutionclindamycin injection
PREMIERProRxn
300 mg/ 50 mL*in 5% DextroseRx only
NDC 0009-3470-02Contains 24 of NDC 0009-3470-01Code 2G3470

NDC 0009-6780-01
Cleocin Phosphate IV Solutionclindamycin injection
600 mg/ 50 mL* in 5% DEXTROSE Rx only
For Intravenous Use
Code 2G3471Sterile, Nonpyrogenic
GALAXY Single Dose Container
PREMIERProRxn
Distributed byPharmacia & Upjohn CoDivision of Pfizer IncNew York, NY 10017
PREMIERProRx is a registered trademarkof Premier Healthcare Alliance, L.P.,used under license.

2 x 12 x 50 mL Single Dose Containers Contains 2 boxes of 12 of NDC 0009-6780-01
Cleocin Phosphate IV Solution clindamycin injection
PREMIERProRxn
600 mg/ 50 mL*in 5% DextroseRx only
NDC 0009-6780-02Contains 24 of NDC 0009-6780-01 Code 2G3471

NDC 0009-9890-01
Cleocin Phosphate IV Solutionclindamycin injection
900 mg/ 50 mL* in 5% DEXTROSE Rx only
For Intravenous Use
Code 2G3472Sterile, Nonpyrogenic
GALAXY Single Dose Container
PREMIERProRxn
Distributed byPharmacia & Upjohn CoDivision of Pfizer IncNew York, NY 10017
PREMIERProRx is a registered trademarkof Premier Healthcare Alliance, L.P.,used under license.

2 x 12 x 50 mL Single Dose Containers Contains 2 boxes of 12 of NDC 0009-9890-01
Cleocin Phosphate IV Solution clindamycin injection
PREMIERProRxn
900 mg/ 50 mL*in 5% DextroseRx only
NDC 0009-9890-02Contains 24 of NDC 0009-9890-01 Code 2G3472

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Get Price

Clindamycin Phosphate (Cleocin Phosphate)

Trade Name : Cleocin Phosphate

INJECTION, SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what
you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Clindamycin Phosphate (Cleocin Phosphate)

Trade Name : Cleocin Phosphate

INJECTION, SOLUTION

Delivery Process

Product information is meant for

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

Packaging and Delivery

About GNH

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Fluoxetine Hydrochloride (Fluoxetine)

Metoprolol Succinate (Metoprolol Succinate)

Losartan Potassium (Losartan Potassium)

Browse Our Services And Processes

Disclaimer

Browse from other international pharmaceuticals

General

US NDC

Canadian DIN

Swiss Drugs

NZ Drugs

FAQ

Can’t find what you’re looking for?

COMPANY

SERVICES

QUICK LINKS

CONTACT US

Can’t find what
you’re looking for?